IBI305

Dosage & preparation

Risks & contraindications

Interactions

Comparisons

Background

Evidence quality

Highlighted claims

• IBI305 is a bevacizumab biosimilar developed in China with domestic regulatory approval and coverage under China's national insurance scheme. — CapeOX (capecitabine and oxaliplatin) combined with sintilimab and bevacizumab biosimilar (IBI305) for first-line treatment of advanced gastric or oesophagogastric junction adenocarcinoma: study protocol for a single-arm, phase Ib/II trial
• The most commonly reported adverse effects of IBI305 in prior clinical trials are hypertension and epistaxis. — CapeOX (capecitabine and oxaliplatin) combined with sintilimab and bevacizumab biosimilar (IBI305) for first-line treatment of advanced gastric or oesophagogastric junction adenocarcinoma: study protocol for a single-arm, phase Ib/II trial
• IBI305 is available at approximately 30% lower cost than the originator bevacizumab product (Avastin) in Chinese healthcare settings. — CapeOX (capecitabine and oxaliplatin) combined with sintilimab and bevacizumab biosimilar (IBI305) for first-line treatment of advanced gastric or oesophagogastric junction adenocarcinoma: study protocol for a single-arm, phase Ib/II trial
• If IBI305 is stopped for any reason, continuation of sintilimab may be considered following thorough physician evaluation of the patient's status. — CapeOX (capecitabine and oxaliplatin) combined with sintilimab and bevacizumab biosimilar (IBI305) for first-line treatment of advanced gastric or oesophagogastric junction adenocarcinoma: study protocol for a single-arm, phase Ib/II trial
• Evidence from ORIENT-32 and ORIENT-31 demonstrates that the sintilimab-IBI305 combination is safe and effective across multiple solid tumour types. — CapeOX (capecitabine and oxaliplatin) combined with sintilimab and bevacizumab biosimilar (IBI305) for first-line treatment of advanced gastric or oesophagogastric junction adenocarcinoma: study protocol for a single-arm, phase Ib/II trial
• Dose modification of IBI305 is generally not recommended as a strategy for managing adverse events. — CapeOX (capecitabine and oxaliplatin) combined with sintilimab and bevacizumab biosimilar (IBI305) for first-line treatment of advanced gastric or oesophagogastric junction adenocarcinoma: study protocol for a single-arm, phase Ib/II trial